List view / Grid view

Neil Clarke

 

article

Next generation antibody therapeutics: Antibody fragments, dual-targeting strategies, and beyond…

A multitude of novel therapeutic antibody formats based on modification…

9 October 2009 | By Dr Martin Scott, Molecular Cell Biologist, Biopharm R&D, GlaxoSmithKline and Dr Neil Clarke, Molecular Cell Biologist and Biology Section Leader, Biopharm R&D, GlaxoSmithKline

A multitude of novel therapeutic antibody formats based on modification of the conventional IgG format have arisen in recent years. The intensification of interest in this area reflects a pressing need for an additional repertoire of therapeutic molecules which retain the exquisite binding specificity and low intrinsic toxicity of monoclonal…

article

RNAi therapeutics: addressing targets?

Gene silencing by RNA interference (RNAi) uses double-stranded RNA to…

2 August 2008 | By

Gene silencing by RNA interference (RNAi) uses double-stranded RNA to shut down gene expression in cells. This provides the possibility that this new methodology could be used in the treatment of disease symptoms and disease processes. A particular attraction of RNAi (as well as other gene knockdown methods of treatment,…